Temsirolimus, an mTOR inhibitor, has demonstrated drug levels in tissue above those in the plasma of glioma patients, yet in another study negligible CSF drug levels were observed in CNS lymphoma patients [34, 35]. This evidence concerns the gene MTOR and glioma.